WIN 64338 hydrochloride

The Uses of WIN 64338 hydrochloride

WIN 64338 Hydrochloride is a non-peptide bradykinin B2 receptor antagonist.

What are the applications of Application

WIN 64338 hydrochloride is a bradykinin B2 R Inhibitor

Biological Activity

win 64338 hydrochloride is a potent and competitive antagonist of bradykinin b2 receptor [1].bradykinin b2 receptor is a g-protein coupled receptor for bradykinin. bradykinin is an inflammatory nonapeptide and plays a critical role in edema, vasodilation, pain fiber stimulation and smooth muscle spasm.win 64338 hydrochloride is a potent and competitive bradykinin b2 receptor antagonist. in human imr-90 cells, win 64338 inhibited bradykinin binding to the bradykinin b2 receptor with ki value of 64 nm and inhibited ca2+ efflux stimulated by bradykinin with pa2 value of 7.1 in a competitive way. win 64338 inhibited guinea pig ileum contractility induced by bradykinin with pa2 value of 8.2 and also inhibited acetyicholine-induced contractility [1]. in iris sphincter isolated from rabbit, win 64338 (1-10 μm) inhibited contractile responses evoked by bradykinin with pkb value of 6.6 [2]. in guinea-pig tracheal smooth muscle cells, win 64338 inhibited inositol phosphate formation induced by bradykinin [3].in guinea-pigs, win 64338 (30 nm) significantly inhibited the increases in plasma extravasation induced by bradykinin via the release of tachykinins from the trigeminal nerve [2].

Storage

Desiccate at +4°C

References

[1]. sawutz dg, salvino jm, dolle re, et al. the nonpeptide win 64338 is a bradykinin b2 receptor antagonist. proc natl acad sci u s a, 1994, 91(11): 4693-4697.
[2]. hall jm, figini m, butt sk, et al. inhibition of bradykinin-evoked trigeminal nerve stimulation by the non-peptide bradykinin b2 receptor antagonist win 64338 in vivo and in vitro. br j pharmacol, 1995, 116(8): 3164-3168.
[3]. scherrer d, schmidlin f, lach e, et al. effect of win 64338, a b2 bradykinin receptor antagonist on guinea-pig tracheal smooth muscle cells in culture. fundam clin pharmacol, 1998, 12(2): 188-193.